Market Cap 103.72M
Revenue (ttm) 0.00
Net Income (ttm) -41.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 237,700
Avg Vol 940,120
Day's Range N/A - N/A
Shares Out 53.46M
Stochastic %K 78%
Beta 0.96
Analysts Sell
Price Target $3.33

Company Profile

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collabora...

Industry: Biotechnology
Sector: Healthcare
Phone: 514-336-0444
Address:
1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, Canada
startedfromdabottom4
startedfromdabottom4 Jul. 6 at 3:42 AM
$MIST let's push $2 this week.
1 · Reply
bigicica
bigicica Jul. 5 at 2:19 PM
$MIST If Trump’s Big Bill leads to real healthcare cost-cutting, it likely benefits MIST. Etripamil offers a cheaper, self-administered alternative to costly ER visits. As for Canada, it doesn’t affect MIST’s U.S. revenue. Etripamil is manufactured and sold in the U.S. through Milestone Pharmaceuticals USA, Inc.
0 · Reply
MrMadsen1
MrMadsen1 Jul. 4 at 11:20 AM
$MIST Is Trump’s Big Bill good for MIST or not? To me, it seems many people will lose healthcare insurance because of this. Buying the nasal spray and self-medicate would be much cheaper, that having to go to the ER right? So the Big Bill ramps up sales for MIST?
2 · Reply
Dsouk
Dsouk Jul. 3 at 5:51 PM
$MIST Love the short and long term of $MIST but I also am liking $STAK
2 · Reply
BioRich
BioRich Jul. 3 at 5:12 PM
$MIST I can see a news drop AH for this. We're about the midpoint of the FDA review period for Milestone's FDA response to the Bullsh*t CRL. Given the success of the $MIST Type-A meeting with the FDA, followed by their immediate response, I see this is a slam dunk. 20% SP jump on the news I believe. Adding $ALT as I know this group likes FDA news opportunities. MIST is about as clear and clean as it gets. They get screwed by the FDA over technicalities and are still extremely strong. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI $IBB $IBBQ
0 · Reply
fack
fack Jul. 3 at 4:33 PM
MONDAY LIST $BULL $18.00 $RFIL $10.00 $BMNR $180.00 $MIST $6.00 $RGTI $20.00
1 · Reply
B2iDigital
B2iDigital Jul. 2 at 8:57 PM
Maxim Group analysts released a research note on Unicycive Therapeutics (Nasdaq: $UNCY) following the company’s Complete Response Letter (CRL) from the FDA regarding its oxylanthanum carbonate (OLC) application. Unicycive Therapeutics is a B2i Digital Featured Company. View their comprehensive profile at https://b2idigital.com/unicycive. According to Maxim analyst Jason McCarthy, while the CRL delays commercialization, it “could actually be viewed as a derisking event” because the FDA’s concerns were limited to third-party manufacturing compliance issues rather than the drug’s safety or efficacy data. Key points from the Maxim analysis: - The CRL was based solely on cGMP deficiencies at a third-party manufacturing vendor. - No issues were raised regarding OLC’s preclinical, clinical, or safety data. - Unicycive had already identified a backup manufacturing vendor as part of its redundancy strategy. - The company expects to meet with the FDA in a Type A meeting during Q3 2025 to determine next steps. McCarthy maintains a Buy rating with a $30 price target, stating that “from a higher level perspective, it seems OLC should gain approval and that’s the key ‘derisking’ takeaway from the CRL.” In the analyst’s opinion, the manufacturing issue represents a regulatory hurdle rather than a fundamental problem with the drug candidate itself. However, the timeline for resolution remains uncertain pending the upcoming FDA meeting. OLC targets hyperphosphatemia in patients with chronic kidney disease on dialysis, potentially offering a reduced pill burden compared to existing treatments through its proprietary nanoparticle technology. Unicycive’s pipeline also includes UNI-494 for the treatment of Acute Kidney Injury (AKI) which can occur due to complications from illness, infections, dehydration, or certain medications. Led by CEO Dr. Shalabh Gupta, MD and a seasoned executive team, including CFO John Townsend, EVP Doug Jermasek, EVP Pramod Gupta, Dr. Atul Khare, Ph.D., M.B.A., and Dr. Guru Reddy, Unicycive is dedicated to its mission of addressing unmet needs in kidney disease treatment. Please visit Unicycive and B2i Digital to learn more and follow Unicycive as the company advances innovative treatments for kidney disease. DISCLOSURE: Management of B2i Digital owns shares of unrestricted UNCY stock as of July 2, 2025. The opinions and points outlined in the Maxim Research note are solely those of the analyst. B2i Digital does not verify, validate, confirm or offer any opinions of its own. B2i Digital is solely sharing the highlights from the Maxim Research note as a convenience to interested parties. This post is not intended to solicit the sale of UNCY or any security, and it is not intended to offer any opinion on UNCY as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclaimer in the Risks and Disclosures section of https://b2idigital.com/unicycive $MIST, $TNXP, $CDTX
3 · Reply
nastento
nastento Jul. 2 at 11:09 AM
$MIST to all you idiots out there who said the facility was never inspected
4 · Reply
ShorterNew
ShorterNew Jul. 2 at 10:06 AM
$MIST I see an inspection completed in November on the facility according to FDA with VAI classification. If it’s right after ownership change, then chances are that it will be Class 1.
6 · Reply
BinaryLogic
BinaryLogic Jul. 2 at 1:51 AM
$MIST $VTYX $IMRX $UNCY $SCNX [Again] SCNX has two (2) FDA approved drugs scheduled for 2H-2025 commercialization, IP rights through 2041, and executive appointments with more than 65YR combined experience launching/commercializing pharmaceuticals. They have secured a manufacturer and Syneos Health ($4BILS M&S Company) to support commercialization targeting more than $500MILS combined market scope. 8.8Mils float, $10-15Mils market cap. The stock is Oversold on the 3YR Weekly, just now breaking above $1.2 prior resistance. It is my hope that $1.2 will hold as support and provide the foundation to a next-level move. The stock was trading at/around $6.0 at the start of the year PRIOR to FDA approval and commercialization on ArbliTM (hypertension). Multiplier upside (IMO). https://www.stocktitan.net/news/SCNX/scienture-holdings-inc-issues-annual-letter-to-kvovd384zgvj.html
1 · Reply
Latest News on MIST
FDA Issues Complete Response Letter for Etripamil for PSVT

Mar 28, 2025, 7:00 AM EDT - 3 months ago

FDA Issues Complete Response Letter for Etripamil for PSVT


Milestone Pharmaceuticals: Worthy Of A Dart Throw

May 22, 2023, 2:37 PM EDT - 2 years ago

Milestone Pharmaceuticals: Worthy Of A Dart Throw


startedfromdabottom4
startedfromdabottom4 Jul. 6 at 3:42 AM
$MIST let's push $2 this week.
1 · Reply
bigicica
bigicica Jul. 5 at 2:19 PM
$MIST If Trump’s Big Bill leads to real healthcare cost-cutting, it likely benefits MIST. Etripamil offers a cheaper, self-administered alternative to costly ER visits. As for Canada, it doesn’t affect MIST’s U.S. revenue. Etripamil is manufactured and sold in the U.S. through Milestone Pharmaceuticals USA, Inc.
0 · Reply
MrMadsen1
MrMadsen1 Jul. 4 at 11:20 AM
$MIST Is Trump’s Big Bill good for MIST or not? To me, it seems many people will lose healthcare insurance because of this. Buying the nasal spray and self-medicate would be much cheaper, that having to go to the ER right? So the Big Bill ramps up sales for MIST?
2 · Reply
Dsouk
Dsouk Jul. 3 at 5:51 PM
$MIST Love the short and long term of $MIST but I also am liking $STAK
2 · Reply
BioRich
BioRich Jul. 3 at 5:12 PM
$MIST I can see a news drop AH for this. We're about the midpoint of the FDA review period for Milestone's FDA response to the Bullsh*t CRL. Given the success of the $MIST Type-A meeting with the FDA, followed by their immediate response, I see this is a slam dunk. 20% SP jump on the news I believe. Adding $ALT as I know this group likes FDA news opportunities. MIST is about as clear and clean as it gets. They get screwed by the FDA over technicalities and are still extremely strong. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI $IBB $IBBQ
0 · Reply
fack
fack Jul. 3 at 4:33 PM
MONDAY LIST $BULL $18.00 $RFIL $10.00 $BMNR $180.00 $MIST $6.00 $RGTI $20.00
1 · Reply
B2iDigital
B2iDigital Jul. 2 at 8:57 PM
Maxim Group analysts released a research note on Unicycive Therapeutics (Nasdaq: $UNCY) following the company’s Complete Response Letter (CRL) from the FDA regarding its oxylanthanum carbonate (OLC) application. Unicycive Therapeutics is a B2i Digital Featured Company. View their comprehensive profile at https://b2idigital.com/unicycive. According to Maxim analyst Jason McCarthy, while the CRL delays commercialization, it “could actually be viewed as a derisking event” because the FDA’s concerns were limited to third-party manufacturing compliance issues rather than the drug’s safety or efficacy data. Key points from the Maxim analysis: - The CRL was based solely on cGMP deficiencies at a third-party manufacturing vendor. - No issues were raised regarding OLC’s preclinical, clinical, or safety data. - Unicycive had already identified a backup manufacturing vendor as part of its redundancy strategy. - The company expects to meet with the FDA in a Type A meeting during Q3 2025 to determine next steps. McCarthy maintains a Buy rating with a $30 price target, stating that “from a higher level perspective, it seems OLC should gain approval and that’s the key ‘derisking’ takeaway from the CRL.” In the analyst’s opinion, the manufacturing issue represents a regulatory hurdle rather than a fundamental problem with the drug candidate itself. However, the timeline for resolution remains uncertain pending the upcoming FDA meeting. OLC targets hyperphosphatemia in patients with chronic kidney disease on dialysis, potentially offering a reduced pill burden compared to existing treatments through its proprietary nanoparticle technology. Unicycive’s pipeline also includes UNI-494 for the treatment of Acute Kidney Injury (AKI) which can occur due to complications from illness, infections, dehydration, or certain medications. Led by CEO Dr. Shalabh Gupta, MD and a seasoned executive team, including CFO John Townsend, EVP Doug Jermasek, EVP Pramod Gupta, Dr. Atul Khare, Ph.D., M.B.A., and Dr. Guru Reddy, Unicycive is dedicated to its mission of addressing unmet needs in kidney disease treatment. Please visit Unicycive and B2i Digital to learn more and follow Unicycive as the company advances innovative treatments for kidney disease. DISCLOSURE: Management of B2i Digital owns shares of unrestricted UNCY stock as of July 2, 2025. The opinions and points outlined in the Maxim Research note are solely those of the analyst. B2i Digital does not verify, validate, confirm or offer any opinions of its own. B2i Digital is solely sharing the highlights from the Maxim Research note as a convenience to interested parties. This post is not intended to solicit the sale of UNCY or any security, and it is not intended to offer any opinion on UNCY as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclaimer in the Risks and Disclosures section of https://b2idigital.com/unicycive $MIST, $TNXP, $CDTX
3 · Reply
nastento
nastento Jul. 2 at 11:09 AM
$MIST to all you idiots out there who said the facility was never inspected
4 · Reply
ShorterNew
ShorterNew Jul. 2 at 10:06 AM
$MIST I see an inspection completed in November on the facility according to FDA with VAI classification. If it’s right after ownership change, then chances are that it will be Class 1.
6 · Reply
BinaryLogic
BinaryLogic Jul. 2 at 1:51 AM
$MIST $VTYX $IMRX $UNCY $SCNX [Again] SCNX has two (2) FDA approved drugs scheduled for 2H-2025 commercialization, IP rights through 2041, and executive appointments with more than 65YR combined experience launching/commercializing pharmaceuticals. They have secured a manufacturer and Syneos Health ($4BILS M&S Company) to support commercialization targeting more than $500MILS combined market scope. 8.8Mils float, $10-15Mils market cap. The stock is Oversold on the 3YR Weekly, just now breaking above $1.2 prior resistance. It is my hope that $1.2 will hold as support and provide the foundation to a next-level move. The stock was trading at/around $6.0 at the start of the year PRIOR to FDA approval and commercialization on ArbliTM (hypertension). Multiplier upside (IMO). https://www.stocktitan.net/news/SCNX/scienture-holdings-inc-issues-annual-letter-to-kvovd384zgvj.html
1 · Reply
Zerocool510
Zerocool510 Jul. 1 at 11:55 PM
$MIST did something happen for that drop? Or was it just shorts doing their thing?
1 · Reply
Idgaf1972
Idgaf1972 Jul. 1 at 6:39 PM
$MIST Long here……I held after the CRC so I haven’t lost anything yet……I am hoping for a Class 1 but FDA guidelines make this a Class 2 because of the reinspection. Now, we know the FDA has undergone some changes so you never know if they give the benefit of the doubt and give this a Class 1. Regardless, this should be approved no later than January. The only issue is just if they have enough money to get there…….
4 · Reply
CoinRaider
CoinRaider Jul. 1 at 5:34 PM
$MIST Primed for launch if class 1 is received.
1 · Reply
Rroper
Rroper Jul. 1 at 4:30 PM
$MIST Very nice. Paytience
1 · Reply
bobbyhughes611
bobbyhughes611 Jul. 1 at 3:38 PM
$MIST I have seen people post a list of completed inspections before. Has anyone seen that list before/ have it. The big point maybe only point for if class 1 or 2 is if an inspection is still needed or already occurred. Seemingly that’s it
1 · Reply
TheGreedyGrinch
TheGreedyGrinch Jun. 30 at 10:01 PM
$MIST It would be bullish if that $1.94 holds throughout afterhours and doesn't retract like it normally does
1 · Reply
80sActionHero
80sActionHero Jun. 30 at 8:18 PM
$MIST Do we know what day or time frame we're expecting to hear back whether it's class 1 or class 2? To avoid confusion, I'm not asking about the 2 to 6 month review period for approval once we know what class it's going to be. I'm asking when we find out the class.
3 · Reply
OGLUCIDBULL
OGLUCIDBULL Jun. 30 at 7:35 PM
$MIST :))))
0 · Reply
B2iDigital
B2iDigital Jun. 30 at 7:34 PM
Unicycive Therapeutics (Nasdaq: UNCY) today announced receipt of a Complete Response Letter (CRL) from the U.S. FDA regarding its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC), an investigational treatment for hyperphosphatemia in patients with chronic kidney disease on dialysis. Unicycive Therapeutics is a B2i Digital Featured Company. View its investor profile at https://b2idigital.com/unicycive. According to the company, the CRL cited manufacturing deficiencies identified during an inspection of a third-party vendor associated with its main CDMO. These deficiencies were not related to OLC itself, and the FDA raised no concerns about the clinical, pre-clinical, or safety data submitted as part of the application.Unicycive also confirmed that a second manufacturing vendor—previously engaged as a back-up—has already produced OLC drug product and may support the resolution of the issues identified in the CRL. “We plan to immediately seek a Type A meeting with the Agency to gain alignment on the best strategy to ensure rapid resolution of the CRL,” said Shalabh Gupta, MD, M.D., Chief Executive Officer of Unicycive. “With a second manufacturing vendor identified that has produced OLC drug product, we remain optimistic about our ability to bring this promising new treatment option to patients with CKD on dialysis who are managing hyperphosphatemia, and we plan to provide an update as soon as we have additional clarity on next steps from the FDA.” Unicycive reports an unaudited cash balance of approximately $20.7 million, with runway expected into the second half of 2026. Read the full press release here: https://www.globenewswire.com/news-release/2025/06/30/2907157/0/en/Unicycive-Therapeutics-Announces-Receipt-of-Complete-Response-Letter-for-Oxylanthanum-Carbonate-for-the-Treatment-of-Hyperphosphatemia-in-Patients-with-Chronic-Kidney-Disease-on-Dialysis.html Led by CEO Dr. Shalabh Gupta and a seasoned executive team, including CFO John Townsend, EVP Doug Jermasek, EVP Pramod Gupta, Dr. Atul Khare, Ph.D., M.B.A., and Dr. Guru Reddy, Unicycive is dedicated to its mission of addressing unmet needs in kidney disease treatment. Please visit Unicycive (https://unicycive.com/) and B2i Digital (https://b2idigital.com/) to learn more and follow Unicycive as the company advances innovative treatments for kidney disease. DISCLOSURE: Management of B2i Digital owns shares of unrestricted UNCY stock as of June 30, 2025. This post is not intended to solicit the sale of UNCY or any security, and it is not intended to offer any opinion on UNCY as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclaimer in the Risks and Disclosures section of https://b2idigital.com/unicycive. $MIST, $TNXP, $CDTX
1 · Reply
astroplane
astroplane Jun. 30 at 7:03 PM
$MIST looks like canada is backing down on the digital services tariff.
0 · Reply
H3rc1y
H3rc1y Jun. 30 at 2:13 PM
$UNCY it has $MIST written all over it. Already re-opened a small position, will wait to see the price action in the upcoming days and will buy much more sub 5. I expect a great recovery in the upcoming 2-3 months.
2 · Reply
TheGreedyGrinch
TheGreedyGrinch Jun. 30 at 1:39 PM
$MIST MIST climbing nicely for that soon to be break out run
0 · Reply